The University of California San Francisco (UCSF) will participate in the clinical trials of the North American Brain Tumor Consortium (NABTC). Member Institutions of the NABTC will include UCSF, the University of Wisconsin, the University of Pittsburgh, Dana Farber Cancer Center, MD Anderson Cancer Center, the Neuro-Oncology Branch at the National Institutes of Health, the University of California, Los Angeles, Memorial Sloan Kettering Cancer Center and the Pharmacokinetics Center at the University of Texas San Antonio. UCSF will be the Lead Institution and Dr. Prados the Group Leader for the NABTC. Dr. Chang will be the Principal Investigator for this Member Institution grant. The focus of this grant will be to continue to initiate and carefully analyze data generated from investigational phase I/II trials in adult patients with primary brain tumors with the emphasis on malignant glioma. Patients at UCSF will be evaluated and treated by a multidisciplinary team composed of neuro-oncologists, medical oncologists, neurosurgeons, radiation oncologists, neuropathologists, neuroradiologists, and clinical research nurses, with the data monitored and evaluated by dedicated data managers. Tissue obtained from patients at the time of surgery will be collected and stored in a tissue bank for ongoing and future laboratory based studies, as well as for clinical-laboratory correlations as they develop over the period of this grant. Dedicated neuroradiologists and state of the art neuroimaging capabilities exist to develop imaging projects along with the clinical studies planned. The effort will be multi-institutional with the goals to increase patient accrual for rapid study determinations; to share human tissue specimens between Member Institutions with specialized interest or expertise, and most importantly, to cooperate in a creative effort to maintain the highest level of interest in laboratory-based translational clinical research. The UCSF institutional and NABTC multi-institutional effort will be intimately linked with the ongoing interests, needs, and support of the Cancer Therapy Evaluation Program (CTEP) and the Radiation Research Program (RRP) of the Division of Cancer Treatment. The overall goal of this program is to more effectively treat patients with primary brain tumors, especially malignant glioma, with the purpose of increasing the duration and quality of survival.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA062422-12
Application #
7014584
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O2))
Program Officer
Wu, Roy S
Project Start
1994-03-25
Project End
2008-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
12
Fiscal Year
2006
Total Cost
$139,768
Indirect Cost
Name
University of California San Francisco
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Taylor, Jennie W; Parikh, Mili; Phillips, Joanna J et al. (2018) Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol 140:477-483
Vivanco, Igor; Robins, H Ian; Rohle, Daniel et al. (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-71
Norden, Andrew D; Raizer, Jeffrey J; Abrey, Lauren E et al. (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211-7
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95-103
Iwamoto, Fabio M; Lamborn, Kathleen R; Robins, H Ian et al. (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12:855-61
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12:87-94
Guo, Deliang; Prins, Robert M; Dang, Julie et al. (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2:ra82
Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G et al. (2008) Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10:631-42
Lamborn, Kathleen R; Yung, W K Alfred; Chang, Susan M et al. (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-70
Prados, Michael D; Yung, W K A; Wen, Patrick Y et al. (2008) Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 61:1059-67

Showing the most recent 10 out of 23 publications